Neuraptive Therapeutics, Inc. Announces Key Organizational Updates to Advance Its Path Toward Commercialization
Neuraptive Therapeutics has announced two key leadership appointments aimed at strengthening both its corporate governance and financial infrastructure as the company advances its development pipeline focused on peripheral nerve injury treatments. The company has named Ulf Wiinberg to its Board of Directors and appointed William “Bill” MacKenzie as Senior Vice President – Finance, marking a strategic expansion of its executive and advisory capabilities.
The appointments come at a pivotal stage for Neuraptive Therapeutics, as the company continues to develop and position its lead therapeutic candidate, NTX-001, toward potential commercialization. By bringing in executives with extensive global pharmaceutical and biotech experience, the company is signaling its intent to strengthen operational readiness, enhance strategic execution, and support long-term value creation.
Ulf Wiinberg Joins the Board of Directors
Ulf Wiinberg is a highly experienced global biopharmaceutical executive with a career spanning senior leadership roles across major pharmaceutical and healthcare organizations. In his new role as a member of Neuraptive Therapeutics’ Board of Directors, he will provide strategic oversight and industry guidance, particularly in areas related to drug development strategy, commercialization pathways, and global market expansion.
Wiinberg most recently served as Chief Executive Officer of X-Vax Technology, Inc., where he led the company from 2017 to 2024. Prior to that, he held the position of CEO at H. Lundbeck A/S, a Denmark-based global pharmaceutical company specializing in central nervous system disorders, from 2008 to 2014. During his tenure at Lundbeck, he oversaw significant international growth and strategic transformation efforts.
Earlier in his career, Wiinberg spent six years at Wyeth, where he was a member of the company’s Management Committee from 2002 to 2008. During this period, he held multiple senior leadership positions, including Worldwide President of Wyeth Consumer Healthcare from 2002 to 2005. He later served as President of Europe, Middle East, and Africa (EMEA) operations until 2008, when Wyeth was acquired by Pfizer.
In addition to his executive experience, Wiinberg currently serves on several corporate boards across the global life sciences and industrial sectors. His board positions include UCB, a leading global biopharmaceutical company headquartered in Brussels, Belgium; Alfa Laval AB, a Swedish industrial technology company based in Lund; SIGRID Therapeutics AB in Stockholm, Sweden; and MiNK Therapeutics, Inc., based in Lexington, Massachusetts. These roles reflect his broad exposure to both established pharmaceutical companies and emerging biotech firms.
Commenting on his appointment, Wiinberg expressed enthusiasm about joining Neuraptive Therapeutics at a critical stage of its growth. He highlighted the company’s mission to address significant unmet medical needs in patients suffering from peripheral nerve injuries, a condition area that remains underserved despite advances in neurology and regenerative medicine. He emphasized his commitment to collaborating with the board and management team to support the company’s strategic development and future commercialization efforts.
His appointment is expected to strengthen Neuraptive’s board-level expertise in global pharmaceutical operations, regulatory strategy, and commercialization planning—areas that are particularly important as the company transitions from development-stage activities toward potential late-stage clinical and market-focused milestones.
Appointment of Bill MacKenzie as Senior Vice President – Finance
Alongside its board expansion, Neuraptive Therapeutics has also appointed William “Bill” MacKenzie as Senior Vice President – Finance, where he will lead the company’s enterprise-wide finance function and contribute to the development of its operational and financial infrastructure.
MacKenzie had been serving as a consultant and Head of Finance at Neuraptive since March 2025, providing continuity in financial oversight prior to his formal appointment. In his expanded role, he will be responsible for overseeing financial planning and analysis, accounting operations, capital allocation strategy, and overall financial governance as the company scales its operations.
MacKenzie brings more than a decade of experience in biotechnology financial leadership, with a career trajectory that spans roles from senior accounting positions to executive leadership in finance. His background includes leadership responsibilities across revenue management, commercial finance, and research and development (R&D) financial planning.
Prior to joining Neuraptive, MacKenzie held senior finance roles at several biotechnology and healthcare companies. From 2022 to 2024, he worked at Sage Therapeutics, a biopharmaceutical company focused on brain health disorders. Before that, he served at Prelude Therapeutics between 2021 and 2022, where he contributed to financial operations during a period of clinical pipeline advancement.
Earlier, he held a role at LifeScan from 2020 to 2021, followed by a longer tenure at Zyla Life Sciences from 2015 to 2020, where he gained extensive experience in managing financial operations across both public and private equity-backed healthcare environments. Across these positions, MacKenzie developed expertise in supporting companies through regulatory milestones, commercialization planning, and corporate restructuring processes.
Notably, his career has also included involvement with multiple FDA-approved product cycles, giving him firsthand experience in the financial complexities associated with late-stage clinical development and market entry. His background in navigating corporate restructuring further strengthens his ability to support biotech organizations operating in capital-intensive environments.
In his new role at Neuraptive, MacKenzie will play a central role in strengthening financial discipline, improving operational efficiency, and supporting strategic investment decisions as the company advances NTX-001 and evaluates future pipeline opportunities.
Executive Leadership Commentary
Bob Radie, Chairman of the Board and Chief Executive Officer of Neuraptive Therapeutics, welcomed both appointments, emphasizing the value each executive brings to the organization at this stage of its development.
He highlighted MacKenzie’s deep financial expertise as critical to supporting the continued advancement of NTX-001 toward commercialization. According to Radie, strong financial leadership will be essential as the company manages the complexities of clinical development, regulatory engagement, and potential market launch preparation.
Regarding Wiinberg’s appointment, Radie noted that his global pharmaceutical leadership experience and strategic insight will be highly valuable to the board and executive team. He emphasized that Wiinberg’s background across large multinational pharmaceutical companies and emerging biotech organizations will help guide Neuraptive’s long-term strategic direction.
Together, the appointments are expected to enhance both the governance and operational capabilities of Neuraptive Therapeutics as it continues to develop therapies aimed at addressing peripheral nerve injuries, an area with significant unmet medical need.
Strategic Implications for Neuraptive Therapeutics
The addition of seasoned leadership in both board and executive finance roles reflects Neuraptive’s broader strategy of strengthening its organizational foundation as it advances through critical development stages. As biotech companies approach late-stage clinical programs and potential commercialization, leadership experience in global pharmaceutical markets and financial management becomes increasingly important.
Wiinberg’s extensive background in leading multinational pharmaceutical operations, combined with MacKenzie’s deep expertise in biotech financial management, positions the company to better navigate the complex intersection of clinical development, regulatory requirements, and commercial readiness.
Peripheral nerve injury treatment remains a challenging and underdeveloped therapeutic area, and Neuraptive’s lead candidate NTX-001 represents a key focus for the company’s research and development efforts. As the program progresses, the company’s ability to integrate strong governance, financial discipline, and strategic oversight will play a critical role in determining its long-term success.
Neuraptive Therapeutics’ appointments of Ulf Wiinberg and William “Bill” MacKenzie mark a significant strengthening of the company’s leadership structure. By adding a globally experienced pharmaceutical executive to its board and an accomplished biotech finance leader to its senior management team, the company is reinforcing its commitment to advancing NTX-001 and building a sustainable operational foundation.
These leadership additions are expected to enhance strategic decision-making, improve financial governance, and support Neuraptive’s transition toward later-stage development and potential commercialization in the peripheral nerve injury treatment space.
About Neuraptive
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company’s headquarters are in Chesterbrook, PA.
